Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Mental Disorders

Treatments: Drug: Paroxetine

Study type: Observational

Funder types: Industry

Identifiers

NCT01371461

112304

Details and patient eligibility

About

Overall improvement, severities and changes of specific clinical symptoms were surveyed in outpatients with depression or in a depressed state to evaluate the efficacy and safety of PAXIL tablets in patients in whom the PAXIL dose was increased and those treated with a constant dose.

Enrollment: 390 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who is 18 years or more
• Subjects diagnosed with depression or in a depressed state

Exclusion criteria

• Subjects who have been treated with paroxetine prior to this investigation
• Subjects with hypersensitivity to paroxetine
• Subjects taking monoamine oxidase inhibitors (MAOIs) or within 2 weeks of stopping treatment with MAOIs
• Concomitant use in subjects taking pimozide

Trial design

390 participants in 1 patient group

Patients prescribed PAXIL

Description:

Patients with depression or depressed state prescribed PAXIL during study period

Treatment:

Drug: Paroxetine